Storys zum Thema Krebs

14.07.2021 – 08:00
Schweizerischer Nationalfonds / Fonds national suisse
Cancerous tumours: how likely are they to metastasise?
Bern (ots) - A very aggressive type of cancer has provided a team of researchers supported by the Swiss National Science Foundation with an answer to the question of which tumour cells are at risk of spreading. Cancer treatment is sometimes complicated by the heterogeneity of the cells that form the tumour mass. The problem is how to identify the few cells that are capable of triggering metastases. Thanks to work carried ...
mehr
29.06.2021 – 14:07
Pierre Fabre; EORTC
European Organisation for Research and Treatment of Cancer (EORTC) and Pierre Fabre Partner to Address Treatment Gap for Stage 2 Melanoma Patients
Brussels and Castres, France (ots/PRNewswire) - Partnership builds on complementary strengths to advance research in melanoma with a focus on Stage 2 melanoma patients European Organisation for Research and Treatment of Cancer (EORTC) and Pierre Fabre today announced a strategic partnership in support of patients ...
mehr
22.06.2021 – 14:01
Abcam; Pionyr
Pionyr and Abcam extend partnership to evaluate TREM2-expressing cells in cancer patients
South San Francisco, Calif. and Cambridge, England (ots/PRNewswire) - - The partnership will support the progression of PY314, the first of Pionyr's Myeloid Tuning(TM) antibodies to enter the clinic - Pionyr will use Abcam's EPR20243 clone to evaluate TREM2 levels in tissue samples for potential future development ...
mehr
21.06.2021 – 14:00
Epredia
Epredia And Aiforia Announce Partnership For Global Distribution Of AI-powered Pathology Software
Portsmouth, N.h. (ots/PRNewswire) - Epredia, a global leader in precision cancer diagnostics, and Aiforia, a medical software company providing Artificial Intelligence (AI) based solutions for image analysis in pathology, have announced today that they have entered into a commercial distribution agreement for ...
mehr
16.06.2021 – 10:00
Norgine
Norgine B.V. enters into exclusive distribution agreement for the commercialisation of PLENVU® in China with Beijing Podconley Pharmaceutical Technology & Development Co., Ltd.
Amsterdam (ots/PRNewswire) - NORGINE B.V. (Norgine) a leading European specialist pharmaceutical company and Beijing Podconley Pharmaceutical Technology & Development Co., Ltd. (Beijing Podconley), today announced an exclusive distribution agreement by which Beijing Podconley will commercialise Norgine's product ...
mehr
16.06.2021 – 09:00
Debiopharm International SA
DEBIOPHARM AND UBIX THERAPEUTICS LAUNCH RESEARCH TO DEVELOP A NEW ANTI-CANCER MODALITY - ANTIBODY DEGRADUCER® CONJUGATES
Lausanne, Switzerland, Seoul, Republic of Korea (ots) - Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company and Ubix Therapeutics (en.ubixtrx.com), a South Korea-based biotech company today announced their co-research agreement combining two novel proprietary technologies to specifically ...
mehr

14.06.2021 – 09:00
Debiopharm International SA
DEBIOPHARM’S CD37 ANTIBODY DRUG CONJUGATE SHOWS PROMISING PHASE II RESULTS FOR THE TREATMENT OF B-CELL MALIGNANCIES
Lausanne, Switzerland (ots) - - Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive form of Non-Hodgkin’s Lymphoma (NHL), representing 30-40% of cases. Nearly half of DLBCL patients are not cured by first-line treatment, leaving a large number of patients at risk of worsening disease1 - Naratuximab ...
mehr
18.05.2021 – 17:20
Aion Therapeutic Inc.
Combined Apollon and Aion Formulations Kill Breast Cancer Cells Through Multiple Pathways
London and Toronto (ots/PRNewswire) - Apollon Formularies plc (AQSE: APOL) ("Apollon" or the "Company"), a UK based international pharmaceutical company trading on the Aquis Stock Exchange, and Aion Therapeutic Inc. (CSE: AION) ("Aion"), a BC based international pharmaceutical company trading on the Canadian Securities Exchange, are pleased to announce that joint ...
mehr
10.05.2021 – 08:01
Avectas
Avectas announces publication in leading cell therapy journal Cytotherapy of 'A novel non-viral delivery method that enables efficient engineering of primary human T cells for ex vivo cell therapy applications'
Dublin (ots/PRNewswire) - SOLUPORE® technology enables the next-generation of gene-modified cell therapies Irish based cell engineering company, Avectas today announces the publication of 'A novel non-viral delivery method that enables efficient engineering of primary human T cells for ex vivo cell therapy ...
mehr
28.04.2021 – 14:01
Cosmo Pharmaceuticals N.V.
Invitation to Cosmo's GI Genius(TM) Q&A session for investors, analysts and journalist
Dublin (ots/PRNewswire) - Cosmo Pharmaceuticals N.V. (SIX: COPN) ( XETRA: C43) invites investors, financial analysts as well as business and trade media to a conference call Q&A session on the 4th of May 2021 to discuss GI Genius(TM), the first device approved by the US Food and Drug Administration[1] (FDA) that uses artificial intelligence to help detect potential ...
mehr
22.04.2021 – 14:58
Avectas
AVECTAS Leads EUR7.23 million Consortium Awarded Part Funding From Disruptive Technologies Innovation Fund
Dublin (ots/PRNewswire) - Funding to develop high throughput cell engineering technology to manufacture 'off the shelf' cell therapies. Project, led by Avectas in partnership with Bluebridge Technologies and National Institute for Bioprocessing Research and Training (NIBRT), would support Ireland's goal of being at ...
mehr
21.04.2021 – 15:15
Aion Therapeutic Inc.
Aion Therapeutic's Proprietary Mushroom Preparations Shown Effective in Killing Breast Cancer Cells
Toronto (ots/PRNewswire) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announced today that its proprietary and patented combinatorial mushroom preparations AION F7 and AION F8 (collectively, the "Aion Mushroom Preparations" or "Preparations") showed high efficacy in killing HER2+ breast ...
mehr

19.04.2021 – 11:47
Vidac Pharma LTD
Vidac Pharma Secures EUR 20m Capital Commitment From GEM
Ness-Ziona, Israel (ots/PRNewswire) - Vidac Pharma LTD (Vidac) a clinical-stage Israel biopharmaceutical company, announced today that it has signed an agreement with GEM Global Yield LLC SCS ("GEM") a Luxemburg-based private alternative investment group for a EUR 20 million capital commitment. Under the agreement, GEM commits to provide Vidac with a share subscription facility of up to EUR 20 million for a 36-month term ...
mehr
12.04.2021 – 07:00
Cosmo Pharmaceuticals N.V.
Cosmo announces FDA approval of GI Genius(TM) intelligent endoscopy module, its revolutionary Artificial Intelligence device for lesion detection during colonoscopy
Dublin (ots/PRNewswire) - Cosmo Pharmaceuticals NV (SIX: COPN) today announced the FDA approval of GI Genius(TM) intelligent endoscopy system, its revolutionary device for lesion detection during colonoscopy. The GI Genius module FDA approval marks a pivotal milestone for Cosmo after more than 10 years of research ...
mehr
08.04.2021 – 10:01
Bionical Emas
Bionical Emas launches Managed Access Program for JZP 458 - a recombinant Crisantaspase produced in Pseudomonas fluorescens
Willington, England (ots/PRNewswire) - Bionical Emas, a global specialist Clinical Research Organization (CRO) has today announced the launch of a Managed Access Program for Jazz Pharmaceuticals' medicinal product JZP-458 for the treatment of patients with Acute Lymphoblastic Leukaemia (ALL) and Lymphoblastic ...
mehr
16.03.2021 – 08:00
Merck Healthcare Germany GmbH
Merck Reports Topline Data for Bintrafusp Alfa as Second-Line Monotherapy Treatment in Biliary Tract Cancer
Darmstadt, Germany (ots/PRNewswire) - Not intended for US-, Canada- or UK-based media Merck, a leading science and technology company, today announced topline data from the Phase II INTR@PID BTC 047 study evaluating bintrafusp alfa as a monotherapy in the second-line treatment of patients with locally advanced or ...
mehr
11.03.2021 – 15:02
Aion Therapeutic Inc.
Aion Therapeutic Files 4 New Patent Applications (Including for the Treatment of Human Cancers)
Toronto (ots/PRNewswire) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announced today that it has filed 4 new patent applications related to preparations of medicinal and psychedelic mushrooms. The patent applications include use of medicinal mushrooms for the treatment of human cancers including breast cancer, use of combination medical ...
mehr
25.02.2021 – 09:00
Debiopharm International SA
DEBIOPHARM AND GENOME & COMPANY JOIN FORCES TO CREATE NEW HIGHLY SPECIFIC THERAPIES FOR CANCER PATIENTS
Lausanne, Switzerland and Seongnam-si Gyeonggi-do, Republic of Korea (ots) - Korean and Swiss based companies leverage their oncology expertise to initiate a research collaboration to formulate novel antibody-drug conjugate (ADC) candidates Genome & Company (314130, CEO: Jisoo Pae, Hansoo Park), a global leading ...
mehr

17.02.2021 – 13:00
European Society for Medical Oncology (ESMO)
Launch of ESMO Virtual Plenaries Brings Rapid Access to Ground-Breaking Cancer Research
mehr
16.02.2021 – 13:00
SMART Medical Systems Ltd
SMART Medical Systems receives Additional FDA Clearance for its G-EYE® Colonoscope, and Commences Clinical Work in the USA
Ra'anana, Israel (ots/PRNewswire) - SMART Medical has now commenced clinical collaboration with NYU Langone Health introducing its newly FDA-cleared G-EYE® 760 Colonoscope series, based on FUJIFILM Corporation's 510(k) cleared 760 colonoscopes and operating with Fujifilm's state-of-the-art ELUXEO imaging system ...
mehr
08.02.2021 – 10:01
Sophia Genetics
SOPHiA GENETICS and the Spanish Lung Cancer Group Team Up to Explore the Predictive Potential of Multimodal Health Data in Resectable Stage IIIA Non-Small Cell Lung Cancer
Lausanne, Switzerland and Boston (ots/PRNewswire) - SOPHiA GENETICS, a global leader in Data-Driven Medicine, announced today a clinical research partnership initiative with the Spanish Lung Cancer Group to apply its radiomics and multimodal analysis capabilities to predict response to neoadjuvant chemoimmunotherapy ...
mehr
21.12.2020 – 13:59
Servier
Servier to Acquire Agios Pharmaceuticals' Oncology Business
Paris and Boston (ots/PRNewswire) - - Transaction includes commercial, clinical and research-stage oncology portfolio and employees for up to $2 billion plus royalties - Includes Agios' marketed medicine TIBSOVO® and a strong oncology pipeline of Phase 3 and early-stage assets - Acquisition in-line with Servier's strategic ambition to become a recognized and innovative player in oncology, supported by unique drug ...
mehr
26.11.2020 – 17:37
Merck Healthcare Germany GmbH
European Medicines Agency Validates Application for Tepotinib for the Treatment of Advanced NSCLC with METex14 Skipping Alterations
Darmstadt, Germany (ots/PRNewswire) - Merck, a leading science and technology company, today announced that the European Medicines Agency (EMA) has validated for review, the application for tepotinib for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial ...
mehr
25.11.2020 – 11:30
Helsana Gruppe
Helsana Drug Report: Spitex patients exposed to significant medication risks
Zurich (ots) - In 2019, medication costs in Switzerland totalled approximately CHF 7.6 billion. The front runners remained cancer and immune system drugs, followed by nervous system medications and metabolic preparations. The use of biosimilars (generic preparations) offers significant savings potential that unfortunately remains almost completely unexploited. In an ...
mehr

28.10.2020 – 09:00
RARECELLS DIAGNOSTICS
ISET® test results show substantial improvement in early detection of prostate cancer by identifying PSA-positive Circulating Tumor Cells
Paris (ots/PRNewswire) - Rarecells, Inc. (USA), a leading Liquid Biopsy company, is pleased to announce that National Institute of Integrative Medicine's (Melbourne, Australia) researchers obtained striking results in a group of Australian men using the ISET® test for early prostate cancer diagnosis through the ...
mehr
08.10.2020 – 08:01
HARMONY Alliance
The HARMONY Alliance launches HARMONY PLUS, a new public-private partnership to improve outcomes for patients with blood cancers
The Hague, Netherlands (ots/PRNewswire) - - HARMONY PLUS builds upon the success of HARMONY in capitalizing on Big Data to speed up the development of more effective treatments for patients with blood cancers. - HARMONY PLUS will leverage the HARMONY Big Data Platform, a central data poolof anonymized data, ...
mehr
05.10.2020 – 09:00
Debiopharm International SA
Debiopharm and the Japanese Cancer Association Announce Winners of the 2020 JCA-Mauvernay Award
Lausanne (ots) - For its sixteenth edition, the JCA-Mauvernay Award was awarded to Doctor Hideaki Ogiwara and Doctor Keisuke Kataoka Debiopharm (www.debiopharm.com), a Swiss-based global, biopharmaceutical company, presented the JCA-Mauvernay Award on October 3rd to Dr. Hideaki Ogiwara from the Division of Cancer Therapeutics of the National Cancer Center Research ...
mehr
01.10.2020 – 14:00
Debiopharm International SA
DEBIOPHARM LAUNCHES TRILYNX - A LARGE-SCALE PHASE III CLINICAL TRIAL TO FURTHER EVALUATE XEVINAPANT IN THE TREATMENT OF HEAD & NECK CANCER
Lausanne, Switzerland (ots) - First patient dosed in the randomized, placebo-controlled Phase III study of xevinapant (Debio 1143) vs placebo when added to chemoradiotherapy (CRT) in high-risk patients with locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN) Debiopharm (www.debiopharm.com), a ...
mehr
22.09.2020 – 11:00
Debiopharm International SA
DEBIOPHARM HONORED AS A 2020 SWISS BIOTECH SUCCESS STORY WINNER FOR OUTSTANDING ACHIEVEMENTS OVER 40 YEARS
Lausanne, Switzerland (ots) - Debiopharm, (www.debiopharm.com), a Swiss-based biopharmaceutical company today announced being one of the recipients of the 2020 Swiss Biotech Success Story Award for exceptional achievements in the biotech industry. Every year, the Swiss Biotech Association awards companies or ...
mehr
17.09.2020 – 09:00
Debiopharm International SA
DEBIOPHARM TO PRESENT LATE BREAKING HEAD & NECK CANCER ABSTRACT AT THE 2020 EUROPEAN SOCIETY OF MEDICAL ONCOLOGY CONGRESS
Lausanne, Switzerland (ots) - Debiopharm announces the presentation of the 3-year phase II follow-up data along with 2 posters for xevinapant (antagonist of IAP -Inhibitor of Apoptosis Proteins) and WEE1 inhibitor Debio 0123 Debiopharm, ...
Ein Dokument
mehr

Vorherige123456Nächste